Gregory Z Ferl

List of Publications by Year
in descending order

		623734	642732
23	623	14	23
papers	citations	h-index	g-index
24	24	24	851
all docs	docs citations	times ranked	citing authors

#	ARTICLE	IF	CITATIONS
1	A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn). Annals of Biomedical Engineering, 2005, 33, 1640-1652.	2.5	128
2	Estimation of the 18F-FDG Input Function in Mice by Use of Dynamic Small-Animal PET and Minimal Blood Sample Data. Journal of Nuclear Medicine, 2007, 48, 2037-2045.	5.0	64
3	Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 359-364.	7.1	61
4	A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Molecular Cancer Therapeutics, 2006, 5, 1550-1558.	4.1	57
5	Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini‐review on fundamental concepts and applications. Biopharmaceutics and Drug Disposition, 2016, 37, 75-92.	1.9	40
6	Derivation of a Compartmental Model for Quantifying 64Cu-DOTA-RGD Kinetics in Tumor-Bearing Mice. Journal of Nuclear Medicine, 2009, 50, 250-258.	5.0	33
7	An automated method for nonparametric kinetic analysis of clinical DCE‐MRI data: Application to glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine, 2010, 63, 1366-1375.	3.0	33
8	Effects of Anti-VEGF on Predicted Antibody Biodistribution: Roles of Vascular Volume, Interstitial Volume, and Blood Flow. PLoS ONE, 2011, 6, e17874.	2.5	31
9	Development and Evaluation of a Novel Method for Preclinical Measurement of Tissue Vascular Volume. Molecular Pharmaceutics, 2010, 7, 1848-1857.	4.6	23
10	A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies. Clinical and Translational Science, 2018, 11, 296-304.	3.1	22
11	Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational Pharmacology. AAPS Journal, 2018, 20, 107.	4.4	19
12	VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models. Neoplasia, 2019, 21, 1036-1050.	5.3	17
13	Quantification of Antiangiogenic and Antivascular Drug Activity by Kinetic Analysis of DCE-MRI Data. Clinical Pharmacology and Therapeutics, 2012, 92, 118-124.	4.7	16
14	A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-Â activation. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14180-14185.	7.1	15
15	Extending the utility of gene profiling data by bridging microarray platforms. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10585-10587.	7.1	13
16	Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer. Oncotarget, 2019, 10, 6234-6244.	1.8	11
17	Mixed‐effects modeling of clinical DCE‐MRI data: Application to colorectal liver metastases treated with bevacizumab. Journal of Magnetic Resonance Imaging, 2015, 41, 132-141.	3.4	9
18	GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. Magnetic Resonance Imaging, 2013, 31, 618-623.	1.8	7

#	Article	IF	Citations
19	Imaging Reveals Importance of Shape and Flexibility for Glomerular Filtration of Biologics. Molecular Cancer Therapeutics, 2021, 20, 2008-2015.	4.1	7
20	DATforDCEMRI: AnRPackage for Deconvolution Analysis and Visualization of DCE-MRI Data. Journal of Statistical Software, 2011, 44, .	3.7	7
21	Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies. Molecular Cancer Therapeutics, 2020, 19, 1052-1058.	4.1	4
22	GPU-Accelerated Compartmental Modeling Analysis of DCE-MRI Data from Glioblastoma Patients Treated with Bevacizumab. PLoS ONE, 2015, 10, e0118421.	2.5	4
23	Valency of HER2 Targeting Antibodies Influences Tumor Cell Internalization and Penetration. Molecular Cancer Therapeutics, 2021, 20, 1956-1965.	4.1	2